Mathematics
Clinical Trials
100%
Design
95%
Dose Finding
78%
Dose
65%
Toxicity
51%
Biomarkers
49%
Phase I Trial
45%
Immunotherapy
39%
Therapy
34%
Cancer
33%
Continual Reassessment Method
31%
Drugs
27%
Operating Characteristics
27%
Data Augmentation
27%
Adaptive Design
23%
Randomisation
19%
Longitudinal Data
19%
Simulation Study
17%
Missing Data
16%
Evaluate
15%
Interval
15%
Bayesian Design
15%
Efficacy
15%
Chemotherapy
13%
Informative Censoring
13%
Group Sequential
13%
Image Registration
13%
Immune Response
13%
Progression
13%
Bayesian Hierarchical Model
12%
Maximum Tolerated Dose
12%
Latent Class
12%
Random Effects
12%
Hybrid Model
12%
Mixed Effects
11%
Drop out
11%
Leukemia
11%
Multiple Imputation
11%
Performance
11%
Response Time
11%
Survival Time
10%
Model
10%
Screening
9%
End point
9%
Landmarks
9%
Covariates
9%
Baseline
9%
Monitoring
9%
Decision Rules
9%
Regression Analysis
9%
Medicine & Life Sciences
Biomarkers
91%
Neoplasms
53%
Non-Small Cell Lung Carcinoma
51%
Lung Neoplasms
48%
Clinical Trials, Phase I
38%
Random Allocation
37%
Maximum Tolerated Dose
35%
Survival
34%
Hepatocellular Carcinoma
29%
atezolizumab
28%
Adenocarcinoma
28%
Neoplasm Metastasis
27%
Glycopeptides
27%
Progression-Free Survival
26%
Pancreatic Neoplasms
25%
Area Under Curve
25%
Therapeutics
25%
dihydrotetrabenazine
23%
Circulating Neoplastic Cells
22%
Malignant Mesothelioma
21%
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
21%
Clinical Trials
20%
Bevacizumab
20%
Small Cell Lung Carcinoma
20%
Sorafenib
19%
Precision Medicine
19%
Haptoglobins
18%
Confidence Intervals
17%
selinexor
16%
human HP protein
16%
Tumor Biomarkers
16%
Breast Neoplasms
15%
Leukemia
14%
Fibrosis
14%
Accidental Falls
14%
Phase II Clinical Trials
14%
Aurora Kinase A
13%
Hospitalists
13%
Randomized Controlled Trials
13%
lipoprotein-associated coagulation inhibitor
13%
REM Sleep Behavior Disorder
12%
Topotecan
12%
Cranial Irradiation
12%
Mutation
12%
Platelet-Derived Growth Factor Receptors
11%
Squamous Cell Carcinoma of Head and Neck
11%
Serum
11%
Celecoxib
11%
Fibula
11%